Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gamma amino butyric acid controlled-release - Diamyd Medical

Drug Profile

Gamma amino butyric acid controlled-release - Diamyd Medical

Alternative Names: GABA - Diamyd; Gamma-amino-butyric-acid-Diamyd; Oral GABA Therapy - Diamyd; Remygen

Latest Information Update: 15 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diamyd Medical AB
  • Developer Diamyd Medical AB; Uppsala University Hospital
  • Class Amines; Antihyperglycaemics; Butyric acids; Small molecules
  • Mechanism of Action GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus

Most Recent Events

  • 10 May 2023 Topline adverse events data from phase I/II ReGenerate-1 trial in Type 1 diabetes mellitus released by Diamyd Medical
  • 05 Apr 2023 Before March 2023, Diamyd Medical received patent protection in the US and Japan for GABA formulation Remygen®
  • 27 Mar 2023 Pharmacokinetics data from a phase I/II trial in Diabetes mellitus released by Diamyd Medical
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top